Phase Iii Study Of Palbociclib Combined With Endocrine Therapy (Et) In Patients With Hormone-Receptor-Positive (Hr+), Her2-Negative Primary Breast Cancerand With High Relapse Risk After Neoadjuvant Chemotherapy (Nact): First Results From Penelope-B